All In Biotech

NDA 203100 · Gilead Sciences INC

Stribild

Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Disoproxil Fumarate · Oral · Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor; Cytochrome P450 3A Inhibitor; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Sep 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Aug 27, 2012

Approved uses

5

Original approval plus efficacy supplements

Registered trials

155

48 Phase 3, 6 recruiting

FAERS reports

8,967

7,687 serious, 144 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued EMTRIVA or VIREAD, which are components of STRIBILD. Hepatic function should be monitored closely, with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue STRIBILD. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B See full prescribing information for complete boxed warning. Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and HBV who have discontinued EMTRIVA or VIREAD, two of the components of STRIBILD. Hepatic function should be monitored closely in these...

What it is approved for

From the label in effect Feb 4, 2025.

STRIBILD ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of STRIBILD [see Clinical Studies (14) ] . STRIBILD is a four-drug combination of elvitegravir, an HIV integrase strand transfer inhibitor (HIV-1 INSTI), cobicistat, a CYP3A inhibitor, and emtricitabine and tenofovir disoproxil fumarate (TDF), both HIV nucleoside analog reverse transcriptase inhibitors (HIV NRTI) and is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of STRIBILD. ( 1 , 14 )

Mechanism: STRIBILD is a fixed-dose combination of antiretroviral drugs elvitegravir (boosted by the CYP3A inhibitor cobicistat), emtricitabine, and TDF [see Microbiology (12.4) ] .

Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • STRIBILD · COBICISTAT 150MG; ELVITEGRAVIR 150MG; EMTRICITABINE 200MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cobicistat" as an intervention, any sponsor and status, largest first.

All 155 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • bone density decreased4,603
  • renal injury3,312
  • skeletal injury3,030
  • chronic kidney disease2,519
  • tooth loss2,488
  • bone loss2,161
  • osteonecrosis2,117
  • renal failure2,087
  • multiple fractures1,980
  • tooth injury1,979
  • pain1,846
  • emotional distress1,813

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20124
201382
2014373
2015278
2016264
2017231
2018297
2019539
20203,896
20211,444
2022666
2023317
2024280
2025259
202637

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Stribild (Elviteg/Cob/Emtri/Tenofo Disop)

2024 spending

$23.1M

Beneficiaries

632

5,111 claims

Per beneficiary

$36,621

$138.61 per unit

View as table
YearSpending
2020$47,530,535
2021$37,194,003
2022$32,089,678
2023$27,932,986
2024$23,144,779

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 156 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.